What happened
The Massachusetts-based company’s claim that the ‘069 patent, related to technology to administer mRNA vaccines, owned by Arbutus, outlined obvious concepts was rejected Thursday by an administrative tribunal of the US Patent and Trademark Office. U.S.
The patent is allegedly related to lipid nanoparticle (LNP) technology, which helps the human body create its own therapeutic proteins.
A patent attorney, Zachary Silbersher, told Reuters that it was unclear whether the vaccines developed by Moderna, including the one for COVID-19, infringed the Arbutus patent, but Moderna’s efforts to invalidate the ‘069 patent indicate that the company of biotechnology sees it. like an obstacle
“At the end of the day, Arbutus could claim a royalty on the [COVID-19] vaccine, “Silbersher said.
Because it is important
SVB Leerink analysts said Moderna is unlikely to see any immediate financial impact from the patent resolution.
The pharmaceutical company may appeal the court’s decision to the United States Court of Appeals for the Federal Circuit, however, the chances of success are limited.
Price action
The court decision caused Moderna’s shares to drop nearly 10% to $ 75.33 and Arbutus’ shares to nearly 120% to $ 6.20 at the close on Thursday.
In the after hours session, Moderna shares fell an additional 3% to $ 73.09, while Arbutus shares gained 18.9% to $ 7.37.
Related
